Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
February 21, 2018 6:52 AM ESTBaird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.
Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.
"Notable catalysts remain on track for UX007, including potential for... More
Ultragenyx Pharma (RARE) Tops Q4 EPS by 10c
February 20, 2018 4:12 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More